PORTRAZZA
(Necitumumab)Phase 2Monoclonal antibody
Eli LillyPORTRAZZA is a monoclonal antibody that works as a Epidermal Growth Factor Receptor Erbb1 Inhibitor.[2] It is being investigated across 4 indications, with its most advanced program in Phase 2.[1]
PORTRAZZA is one of 99 small molecule programs targeting Lung Cancer. It is currently in Phase 2.
4
Indications
18
Total Trials
3
Active Trials
98
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
254 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Wellcovorin
GGlaxo Dba Glaxosmithkline
Phase 3
Tecentriq
RochePhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Mitosol
UUroGen Pharma Ltd.
Phase 3
TAS 102
Taiho Oncology, Inc.Phase 3
PORTRAZZA
Eli LillyPhase 2
Adjuvant Chemotherapy
NNizhny Novgorod Regional Clinical Oncology Center
Phase 3
Cytokine-Induced Killer Cells
TThe First People's Hospital of Changzhou
Phase 3
SHR-A1811
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
Iron Isomaltoside
TThomas Jefferson University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer7 trials
Show 4 more trials
Lung Cancer4 trials
Metastatic Lung Non-Small Cell Carcinoma2 trials
Interaction1 trial
3 more indications
Nab-paclitaxel1 trial
Squamous Cell Carcinoma1 trial
Regulatory
FDA Approval Timeline[4]
Nov 24, 2015
PORTRAZZA
BLA BLA125547
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Necitumumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]